Eosinophilic Asthma: Half of All Severe Asthma Has a Specific Cause
The catch? Many people with poorly controlled asthma still haven't been tested for it. If your asthma developed in adulthood, resists high-dose inhalers, or comes with nasal polyps, this is worth understanding.
What Makes Eosinophilic Asthma Different
Standard asthma treatment assumes a relatively uniform disease. Eosinophilic asthma is anything but uniform. It's driven by a specific inflammatory cascade called type 2-high inflammation, where signaling molecules (cytokines like IL-4, IL-5, and IL-13) along with epithelial "alarmins" (TSLP and IL-33) recruit and activate eosinophils in the blood, sputum, and airway tissue.
Those eosinophils don't just cause temporary swelling. Persistent eosinophilia promotes airway hyperresponsiveness, smooth muscle thickening, excess mucus production, and fibrosis. Over time, this structural remodeling can lead to fixed airflow limitation, meaning some of the breathing loss becomes permanent, and severe attacks become more frequent.
This is why standard inhaled corticosteroids and long-acting bronchodilators often fall short. They suppress general inflammation but don't specifically shut down the eosinophil-driven pathway causing the most damage.
The Profile That Should Raise a Red Flag
Eosinophilic asthma doesn't look like the classic childhood wheeze-and-allergen story. The research identifies a distinct clinical profile:
- Adult or late-onset: Often starts well past childhood
- Few classic allergies: Not the typical dust-mite-and-pollen pattern
- Fixed airway obstruction: Lung function doesn't fully bounce back
- Frequent exacerbations: Severe attacks despite aggressive inhaler therapy
- Nasal polyps and aspirin sensitivity: Commonly co-occurring
- Oral steroid dependence: Needing repeated or chronic steroid courses to stay stable
That said, eosinophilic asthma isn't one-size-fits-all. Childhood-onset atopic asthma and aspirin-exacerbated respiratory disease also represent eosinophilic phenotypes, though with differing degrees of tissue eosinophilia. Some people have overlap between allergic and eosinophilic patterns, which is actually common and affects treatment choices.
Three Tests That Change Everything
The reason eosinophilic asthma has become a precision medicine target is that it can be identified and monitored with straightforward biomarkers. Three matter most:
| Biomarker | What It Measures | Key Cutoffs |
|---|---|---|
| Blood eosinophil count | Eosinophils circulating in blood | ≥150–300 cells/µL |
| Induced sputum eosinophils | Eosinophils in airway mucus | >2–3% |
| FeNO (fractional exhaled nitric oxide) | A marker of type 2 airway inflammation | Elevated levels suggest eosinophilic activity |
The blood eosinophil count is the most accessible since it comes from a standard blood draw. Sputum eosinophils provide a more direct look at what's happening in the airways, though the test is less widely available. FeNO is a quick, noninvasive breath test.
The critical point: tailoring treatment to these markers reduces exacerbations. This isn't just about labeling the disease. It's about using the numbers to guide therapy in real time.
The Biologics That Actually Target the Problem
International guidelines now recommend biologic drugs specifically for severe eosinophilic asthma that isn't controlled by high-dose inhaled steroids and long-acting bronchodilators. These aren't general immune suppressors. Each targets a specific node in the type 2 inflammatory chain.
| Biologic Class | Drug Names | What It Targets | Key Benefits |
|---|---|---|---|
| Anti-IL-5 / IL-5 receptor | Mepolizumab, reslizumab, benralizumab | IL-5, the main cytokine driving eosinophil production and survival | Reduces blood and sputum eosinophils, cuts exacerbations, improves lung function, spares oral steroids |
| Anti-IL-4/IL-13 | Dupilumab | IL-4 and IL-13, broader type 2 cytokines | Effective in type 2-high eosinophilic and allergic disease |
| Anti-IgE | Omalizumab | IgE, the antibody central to allergic responses | Best where allergic and eosinophilic patterns overlap |
The choice between them isn't random. Eosinophil counts and FeNO thresholds help guide which biologic fits a given patient's inflammatory profile. Someone with late-onset eosinophilic asthma and nasal polyps, for example, is a strong candidate for anti-IL-5 or anti-IL-4/13. Someone with clear IgE sensitization plus eosinophilia might start with anti-IgE or anti-IL-5.
Used alongside optimized inhaler therapy, these treatments substantially reduce exacerbations, improve lung function and quality of life, and, according to the research, make long-term remission a realistic goal for many patients with severe eosinophilic asthma.
Why "Severe Asthma" Deserves a Second Look
The practical takeaway is blunt: if you or someone you know has asthma that stays poorly controlled despite being on high-dose inhalers, the question isn't just "do I need more medication?" It's "has anyone checked whether eosinophils are driving this?"
A blood eosinophil count is cheap and routine. FeNO is a five-minute breath test. Yet many people cycle through escalating doses of general treatments without anyone identifying the specific inflammatory pattern that would qualify them for a biologic that could change the trajectory of their disease.
The research is clear that about half of severe asthma is eosinophilic, that biomarkers can identify it reliably, and that targeted biologics produce outcomes standard therapy cannot. If your asthma fits the profile described here, especially adult onset, frequent flare-ups, nasal polyps, steroid dependence, or fixed obstruction, the most useful thing you can do is ask whether your eosinophil levels have been checked and whether a biologic might be appropriate. That single conversation could be the difference between managing symptoms and actually controlling the disease.
